1. English
  2. English

MASK (Mobile Airways Sentinel Network)

MASK (Mobile Airways Sentinel Network) is a new development of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative. It works closely with POLLAR (Impact of Air POLLution on Asthma and Rhinitis, EIT Health), and collaborates with professional and patient organizations in the field of allergy and airway diseases. MASK proposes real-life care pathways (ICPs) centred around the patient with rhinitis and/or asthma multimorbidity.
Background
Geographical scope: 
International level
Region involved:
Countries involved:
Download information: 
Organisation
Organisation name: 
MACVIA-France
Organisation address: 
MACVIA-France (contre les Maladies Chroniques pour un VIeillissent Actif en France. Fighting chronic diseases for active and healthy ageing in France), Fondation Partenariale FMC VIA-LR, Université Montpellier, Boulevard Henri IV, 34000- Montpellier, France, +33-611-42-88-47 ...
Kind of organisation: 
Hospitals
Primary care centres
Specialised physicians
General practioners
Pharmacists
Nurses
Day care centres
Home care centres
Nursing homes
Informal caregivers
Housing organisations
Private companies
Micro-sized industry
Small-sized industry
Medium-sized industry
Research centres
Academia
NGOs
International/European public authorities
National public authorities
Regional public authorities
Local public authorities
Advocacy organisations patients/users
Advocacy organisations physicians
Viability
Time for deployment: 
Less than a year
Preparation of implementation: 
https://www.mask-air.com/ https://twinning.euforea.eu/ Deployment Many of the GPs that are developed in one region (country) take into account health systems, availability of treatments and legal considerations which makes it difficult to scale up the practice without customization. MASK has...
Investment per citizen / service user / patient: 
Between 100 – 1.000 EUR per targeted citizen / patient
Cost calculation: 
The total cost to develop the practice was less than 2 M€. It is now freely available and the number of users is illimited.
Evidence of practice: 
Documented evidence. Evidence is based on systematic qualitative and quantitative studies
Evidence creation: 
Scientific evidence and conceptual framework for configuring the practice: The scientific evidence is based on a validated “research” tool (The Allergy Diary, –2018) that has led to large scale deployment (MASK-air, 2019–): • Validation of the app using COSMIN guidelines. • Baseline...
Maturity level: 
The practice is “on the market” and integrated in routine use. There is proven market impact, in terms of job creation, spin-off creation or other company growth.
Maturity level detalis: 
As from the very first workshop in 1999, the ARIA initiative has included all stakeholders required to develop a WHO programme on CRDs (GARD). In particular, patient’s organizations were involved. All health care professionals were also involved (physicians, primary care, pharmacists, other health...
Time of impact: 
Long term and sustainable impact – e.g. a long time after the pilot project ended and routine day-to-day operation began
Kind of impact: 
Better quality of life (societal)
Transferability level: 
The innovative practice has been transferred in other locations or regions or national scale in the same country
Transferability details: 
The EIP on AHA includes 74 Reference Sites. The aim of this TWINNING is to transfer innovation from the MASK App to other reference sites. The phenotypic characteristics of rhinitis and asthma multimorbidity in adults and the elderly have been compared using validated mHealth tools (i.e. the...
Initiative
Type of Practice: 
Good practice
Stakeholders concerned: 
Hospitals
Primary care centres
Specialised physicians
General practioners
Pharmacists
Nurses
Informal caregivers
Private companies
Micro-sized industry
Small-sized industry
Medium-sized industry
Research centres
Academia
NGOs
International/European public authorities
National public authorities , WHO
Regional public authorities
Local public authorities
Advocacy organisations patients/users
Advocacy organisations physicians
Advocacy organisations nurses
Advocacy organisations others
Other, please specify
citizens, patients with allergic rhinitis and/ or severe asthma
Reach of initiative: 
> 100,000
Age group: 
< 18
18 – 49
50 - 64
65 - 79
80+
Baseline information: 
The practice includes the care pathways defined in 2014 as well as ICT (Information and Communication Technology) solutions (cell phones for patients, inter-operable tablets for health care professionals and a web-based questionnaire for physicians). The aim is to develop a change management...
Source of funding: 
Private funding